EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study

Sara Ellegaard Paaske iD, Simon Mark Dahl Baunwall iD, Tone Rubak, Nina Rågård, Jens Kelsen, Mette Mejlby Hansen, Anders Bergh Lødrup, Søren Lyhne, Emilie Glavind, Christa Marie Culmback Fernis, Stine Hald, Lise Tornvig Erikstrup und 6 weitere

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70395 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Sara Ellegaard Paaske und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Clostridium Infections, Donor Selection. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Innovationsfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Faecal microbiota transplantation (FMT) is effective for Clostridioides difficile infection (CDI), but real‐world effectiveness data are warranted to refine treatment algorithms. We previously found that FMT effectiveness varied with donors, and the effect of a single capsule FMT administration was lower than expected.

Aims

To improve FMT outcomes through empirical donor exclusion and application of an optimised capsule FMT dosing regimen.

Methods

In this multi‐site Danish quality improvement study, we included patients with CDI treated with capsule‐based FMT from 24 June 2019 to 30 September 2024. The primary outcome was cure of C. difficile ‐associated diarrhoea (CDAD) 8 weeks after FMT. We assessed this using statistical process control charts monitored separately for the primary FMT centre and the external FMT sites. We used multivariable, mixed‐effect logistic regression analysis to evaluate the impact of FMT dosing while adjusting for patient, donor and CDI‐related factors.

Results

We included 1176 patients (1707 FMT treatments). At external FMT sites, the cure rate from one FMT treatment changed from 50% (95% confidence interval (CI): 45%–56%) to 59% (55%–63%) following the exclusion of three low‐performing donors in November 2022. After implementing a two‐dose capsule FMT dosing regimen in February 2024, the cure rate increased to 72% (65%–77%). The impact of the two‐dose capsule FMT dosing regimen remained statistically significant after adjustment (odds ratio 1.22; 95% CI 1.16–1.28; p < 0.001).

Conclusion

Empirical donor selection and a two‐dose capsule FMT regimen improved clinical outcomes in a large‐scale system treating patients with CDI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fecal Microbiota TransplantationClostridium InfectionsDonor SelectionHumansFemaleMaleMiddle AgedQuality ImprovementAgedTreatment OutcomeDenmarkClostridioides difficileAdultAged, 80 and overDiarrhea

Stichwörter der Autor:innen

Clostridioides difficile infectionfaecal microbiota transplantationmicrobiome therapiesquality improvement

Autor:innen und Institutionen

  • Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Geriatrics, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Medicine, Section of Gastroenterology and Hepatology, Gødstrup Hospital, Gødstrup, Denmark.
  • Department of Internal Medicine, Randers Regional Hospital, Randers, Denmark.
  • Department of Medicine, Regional Hospital Horsens, Horsens, Denmark.

ORCID-Profile: Sara Ellegaard Paaske, Simon Mark Dahl Baunwall

Förderung

  • Innovationsfonden

Zitieren

APA

Paaske, S. E., Baunwall, S. M. D., Rubak, T., Rågård, N., Kelsen, J., Hansen, M. M., Lødrup, A. B., Lyhne, S., Glavind, E., Fernis, C. M. C., Hald, S., Erikstrup, L. T., Vinter-Jensen, L., Lal, S., Mikkelsen, S., Erikstrup, C., Dahlerup, J. F., & Hvas, C. L. (2026). Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70395

Vancouver

Paaske SE, Baunwall SMD, Rubak T, Rågård N, Kelsen J, Hansen MM, et al. Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70395

BibTeX
@article{Paaske2026,
  author = {Paaske, Sara Ellegaard and Baunwall, Simon Mark Dahl and Rubak, Tone and Rågård, Nina and Kelsen, Jens and Hansen, Mette Mejlby and Lødrup, Anders Bergh and Lyhne, Søren and Glavind, Emilie and Fernis, Christa Marie Culmback and Hald, Stine and Erikstrup, Lise Tornvig and Vinter-Jensen, Lars and Lal, Simon and Mikkelsen, Susan and Erikstrup, Christian and Dahlerup, Jens Frederik and Hvas, Christian Lodberg},
  title = {Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70395}
}
Kostenlos starten →